GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inogen Inc (NAS:INGN) » Definitions » 5-Year RORE %

Inogen (Inogen) 5-Year RORE % : 69.66% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Inogen 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Inogen's 5-Year RORE % for the quarter that ended in Dec. 2023 was 69.66%.

The industry rank for Inogen's 5-Year RORE % or its related term are showing as below:

INGN's 5-Year RORE % is ranked better than
94.81% of 636 companies
in the Medical Devices & Instruments industry
Industry Median: 0.66 vs INGN: 69.66

Inogen 5-Year RORE % Historical Data

The historical data trend for Inogen's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inogen 5-Year RORE % Chart

Inogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.45 -25.25 -34.07 614.43 69.66

Inogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 614.43 256.65 177.94 117.70 69.66

Competitive Comparison of Inogen's 5-Year RORE %

For the Medical Devices subindustry, Inogen's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inogen's 5-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Inogen's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Inogen's 5-Year RORE % falls into.



Inogen 5-Year RORE % Calculation

Inogen's 5-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -4.41-0.94 )/( -7.68-0 )
=-5.35/-7.68
=69.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 5-year before.


Inogen  (NAS:INGN) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Inogen 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Inogen's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Inogen (Inogen) Business Description

Traded in Other Exchanges
Address
301 Coromar Drive, Goleta, CA, USA, 93117
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, Inogen sells its products through distributors or large gas companies and home oxygen providers. Inogen generates the majority of its revenue in the United States.
Executives
Thomas A. West director C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Stanislav Glezer officer: EVP, Chief Medical Officer C/O INOGEN, INC., 326 BOLLAY DRIVE., GOLETA CA 93117
Jason Somer officer: EVP, Gen. Counsel & Secretary C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Glenn S Boehnlein director 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Mary Kay Ladone director 130 EAST RANDOLPH STREET, SUITE 1000, CHICAGO IL 60601
Kevin M King director C/O AFFYMETRIX, INC., 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Kristin A. Caltrider officer: EVP, CFO and Treasurer C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Anderson Ray Benjamin M director 1100 NORTH WASHINGTON STREET, DELPHI IN 46923
Michael K. Sergesketter officer: EVP, CFO and Treasurer 301 COROMAR DRIVE, GOLETA CA 93117
Raymond Huggenberger director, officer: See Remarks 326 BOLLAY DRIVE, GOLETA CA 93117
Alison Bauerlein officer: See Remarks 326 BOLLAY DRIVE, GOLETA CA 93117
Brenton Taylor officer: Vice President, Engineering 326 BOLLAY DRIVE, GOLETA CA 93117
Elizabeth Mora director C/O MKS INSTRUMENTS, INC., 2 TECH DRIVE, SUITE 201, ANDOVER MA 01810
George J Parr director BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Byron Myers officer: Vice President, Marketing 326 BOLLAY DRIVE, GOLETA CA 93117